Elutia Inc. (ELUT)
| Market Cap | 45.78M -58.7% |
| Revenue (ttm) | 12.29M -15.0% |
| Net Income | 53.38M |
| EPS | 0.87 |
| Shares Out | 42.78M |
| PE Ratio | 1.23 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,702 |
| Open | 1.100 |
| Previous Close | 1.120 |
| Day's Range | 1.050 - 1.115 |
| 52-Week Range | 0.500 - 2.990 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+460.75%) |
| Earnings Date | Mar 11, 2026 |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac pat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for ELUT stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity a...
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year...
Elutia Regains Compliance with Nasdaq Listing Requirements
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received not...
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete ...
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certifie...
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia ...
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m.
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today a...
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief ...
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” ...
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., ...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management -
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selecte...
Elutia to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief ...
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m.
Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux ...
New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices
— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) —
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards
Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope's impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (G...
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
— Innovative approach accelerates new product development and testing — — Innovative approach accelerates new product development and testing —
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m.